Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03377803 · ClinicalTrials.gov registry record · Phase 3
Cantharidin Application in Molluscum Patients
A Phase 3 study, sponsored by Verrica Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 262
- Enrollment target
NCT03377803 is a Phase 3 study that has completed, run by Verrica Pharmaceuticals. The registered enrollment target is 262 participants.
The verdict
NCT03377803, a Phase 3 study, has completed, sponsored by Verrica Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 262 participants
- Enrollment target
Study Summary
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum. VP-102 will be applied once every 21 days for up to 4 applications, to treatable molluscum contagiosum (molluscum) lesions on subjects 2 years and older. Efficacy will be assessed as the proportion of subjects achieving complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit.
Interventions
- COMBINATION_PRODUCT VP-102 - Cantharidin, Topical Film Forming Solution
- COMBINATION_PRODUCT Placebo -Topical Film Forming Solution without VP-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03377803
The ClinicalTrials.gov registry entry for NCT03377803 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verrica Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VP-102 - Cantharidin, Topical Film Forming Solution is the first listed.
NCT03377803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03377803 about?
NCT03377803 is a clinical study titled "Cantharidin Application in Molluscum Patients". This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum. VP-102 will be applied once every 21 days for up to 4 applications, to treatable molluscum contagio...
What is the current status of trial NCT03377803?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 262 participants. The study started on 2018-02-14. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT03377803?
The interventions under investigation include: VP-102 - Cantharidin, Topical Film Forming Solution (COMBINATION_PRODUCT), Placebo -Topical Film Forming Solution without VP-102 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03377803?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.